Torsten O. Nielsen

54.4k total citations · 11 hit papers
241 papers, 31.1k citations indexed

About

Torsten O. Nielsen is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Torsten O. Nielsen has authored 241 papers receiving a total of 31.1k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 108 papers in Cancer Research and 93 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Torsten O. Nielsen's work include Breast Cancer Treatment Studies (84 papers), Sarcoma Diagnosis and Treatment (70 papers) and HER2/EGFR in Cancer Research (51 papers). Torsten O. Nielsen is often cited by papers focused on Breast Cancer Treatment Studies (84 papers), Sarcoma Diagnosis and Treatment (70 papers) and HER2/EGFR in Cancer Research (51 papers). Torsten O. Nielsen collaborates with scholars based in Canada, United States and United Kingdom. Torsten O. Nielsen's co-authors include Maggie C.U. Cheang, Charles M. Perou, Samuel Leung, David Voduc, Matt van de Rijn, Philip S. Bernard, Joel S. Parker, Stephen Chia, Matthew J. Ellis and Robert B. West and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Torsten O. Nielsen

237 papers receiving 30.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Maggie C.U. Cheang et al. Journal of Clinical Oncology profile →
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

2006 3.0k citations Charles M. Perou, Maggie C.U. Cheang et al. profile →
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

2004 2.1k citations Torsten O. Nielsen, Maggie C.U. Cheang et al. Clinical Cancer Research profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. profile →
Metastatic Behavior of Breast Cancer Subtypes

2010 1.6k citations Maggie C.U. Cheang, Torsten O. Nielsen et al. Journal of Clinical Oncology profile →
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

2011 1.5k citations Torsten O. Nielsen, Daniel F. Hayes et al. profile →
Breast Cancer Subtypes and the Risk of Local and Regional Relapse

2010 960 citations K. David Voduc, Maggie C.U. Cheang et al. Journal of Clinical Oncology profile →
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

2008 945 citations Maggie C.U. Cheang, Samuel Leung et al. Clinical Cancer Research profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival

2011 539 citations Samuel Leung, Robert J. Marinelli et al. profile →
The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status

2004 487 citations Robert B. West, Christopher L. Corless et al. American Journal Of Pathology profile →

Peers

Countries citing papers authored by Torsten O. Nielsen

Since Specialization

Citations

This map shows the geographic impact of Torsten O. Nielsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torsten O. Nielsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torsten O. Nielsen more than expected).

Fields of papers citing papers by Torsten O. Nielsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torsten O. Nielsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torsten O. Nielsen. The network helps show where Torsten O. Nielsen may publish in the future.

Co-authorship network of co-authors of Torsten O. Nielsen

This figure shows the co-authorship network connecting the top 25 collaborators of Torsten O. Nielsen. A scholar is included among the top collaborators of Torsten O. Nielsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torsten O. Nielsen. Torsten O. Nielsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DNA demethylating agents suppress preclinical models of synovial sarcoma 2025 ·Journal of Clinical Investigation ·(unknown), Nezha S. Benabdallah, (unknown), Li Li, (unknown), Jinxiu Li, (unknown), Lena Wagner, (unknown), (unknown), (unknown), Lara Carroll, Malay Haldar, Seth M. Pollack, Scott W. Lowe, Torsten O. Nielsen, Ana Banito, Kevin B. Jones	1
2	Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial 2023 ·Histopathology ·Torsten O. Nielsen, Samuel Leung, Nazia Riaz, Anna Marie Mulligan, Zuzana Kos, Anita Bane, Timothy J. Whelan	3
3	Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability 2023 ·Nature Structural & Molecular Biology ·Nezha S. Benabdallah, (unknown), R. Wilder Scott, (unknown), (unknown), F. Kommoss, (unknown), (unknown), Lena Wagner, Francisco J. Sánchez‐Rivera, (unknown), (unknown), Torsten O. Nielsen, T. Michael Underhill, Ana Banito	11
4	Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 2022 ·Clinical Cancer Research ·(unknown), Bethany C. Prudner, Richa Rathore, Katharine E. Caldwell, Carina Dehner, (unknown), (unknown), Neal Poulin, Jennifer K. Sehn, Jason Roszik, Dirk Spitzer, Kevin B. Jones, Regis J. O’Keefe, Torsten O. Nielsen, Eric B. Taylor, Jason M. Held, William G. Hawkins, Brian A. Van Tine	19
5	Ki67 as a Companion Diagnostic: Good or Bad News? 2022 ·Journal of Clinical Oncology ·Mitch Dowsett, Torsten O. Nielsen, David L. Rimm, Daniel F. Hayes, (unknown)	14
6	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial 2022 ·Cancers ·(unknown), Elisabeth Specht Stovgaard, Maj‐Britt Jensen, Karama Asleh, Nazia Riaz, Dongxia Gao, Samuel Leung, Bent Ejlertsen, Anne‐Vibeke Lænkholm, Torsten O. Nielsen	2
7	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial 2020 ·Clinical Cancer Research ·Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O. Nielsen, Heikki Joensuu, E. Aubrey Thompson, Saranya Chumsri	20
8	The epigenomics of sarcoma 2020 ·Nature reviews. Cancer ·Benjamin A. Nacev, Kevin B. Jones, Andrew M. Intlekofer, (unknown), C. David Allis, William D. Tap, Marc Ladanyi, Torsten O. Nielsen	138
9	A Rapid and Cost-Effective Gene Expression Assay for the Diagnosis of Well-Differentiated and Dedifferentiated Liposarcomas 2020 ·Journal of Molecular Diagnostics ·Xiu Q. Wang, (unknown), (unknown), Angela Goytain, Tony Ng, Torsten O. Nielsen	11
10	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas 2020 ·OncoImmunology ·Amanda R. Dancsok, Dongxia Gao, Anna F. Lee, Sonja E. Steigen, Jean‐Yves Blay, David M. Thomas, Robert G. Maki, Torsten O. Nielsen, Elizabeth G. Demicco	125
11	Death by HDAC Inhibition in Synovial Sarcoma Cells 2017 ·Molecular Cancer Therapeutics ·(unknown), Neal Poulin, Jared J. Barrott, (unknown), Alireza Lorzadeh, Ryan Vander Werff, Kevin B. Jones, T. Michael Underhill, Torsten O. Nielsen	26
12	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen 2012 ·Clinical Cancer Research ·Stephen Chia, Vivien Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi L. Vickery, Elaine R. Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen	220
13	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial 2012 ·Clinical Cancer Research ·Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri R. Davies, Inge J. Stijleman, Carole Davis, Mark Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen	105
14	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer breakdown → 2010 ·Clinical Cancer Research ·Torsten O. Nielsen, Joel S. Parker, Samuel Leung, D. Voduc, Mark Ebbert, Tammi L. Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry P. Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis	542
15	Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models 2008 ·Molecular Cancer Therapeutics ·Shuzhen Liu, Hongwei Cheng, Wanda Kwan, Joanna M. Lubieniecka, Torsten O. Nielsen	49
16	Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas 2008 ·Clinical Cancer Research ·Cheng‐Han Lee, Íñigo Espinosa, Suzan Vrijaldenhoven, Subbaya Subramanian, Kelli Montgomery, Shirley Zhu, Robert J. Marinelli, Johannes L. Peterse, Neal Poulin, Torsten O. Nielsen, Robert B. West, C. Blake Gilks, Matt van de Rijn	142
17	Genome-wide transcriptome analysis of nerve sheath tumors 2006 ·Cancer Research ·Subbaya Subramanian, Robert B. West, Torsten O. Nielsen, Brian P. Rubin, Erinn Downs‐Kelly, John R. Goldblum, Shirley Zhu, Kelli Montgomery, Pancras C.W. Hogendoorn, Christopher L. Corless, André M. Oliveira, Christopher D.�M. Fletcher, Matt van de Rijn	1
18	Growth inhibition of synovial sarcoma cells by curcumin 2005 ·Cancer Research ·Joanna M. Lubieniecka, Wanda Kwan, Jefferson Terry, Torsten O. Nielsen	1
19	The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status breakdown → 2004 ·American Journal Of Pathology ·Robert B. West, Christopher L. Corless, Xin Chen, Brian P. Rubin, Subbaya Subramanian, Kelli Montgomery, Shirley Zhu, Catherine A. Ball, Torsten O. Nielsen, Rajiv M. Patel, John R. Goldblum, Patrick O. Brown, Michael C. Heinrich, Matt van de Rijn	487
20	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans 2003 ·American Journal Of Pathology ·Sabine C. Linn, Robert B. West, Jonathan R. Pollack, Shirley Zhu, Tina Hernandez‐Boussard, Torsten O. Nielsen, Brian P. Rubin, Rajiv M. Patel, John R. Goldblum, David Siegmund, David Botstein, Patrick O. Brown, C. Blake Gilks, Matt van de Rijn	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact